Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis - PubMed (original) (raw)
. 1996 Mar-Apr;3(2):89-98.
Affiliations
- PMID: 8729907
Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis
J Deshane et al. Cancer Gene Ther. 1996 Mar-Apr.
Abstract
Methods were developed to achieve targeted eradication of the erbB-2 oncoprotein using gene constructs encoding anti-erbB-2 intracellular single-chain antibodies. This method of genetic intervention caused a marked cytocidal effect in erbB-2-overexpressing human ovarian tumor cells. Evaluation of the mechanistic basis of this phenomenon demonstrated that programmed cell death had been induced. Significantly, no cytocidal effect was observed in non-erbB-2-overexpressing tumors. The induction of apoptosis could be shown to be secondary to the intracellular antibody-mediated ectopic localization of the erbB-2 oncoprotein. Thus, the strategy of selective oncogene "knock-out" using intracellular antibodies represents a novel anticancer gene therapy strategy that offers the potential to achieve highly specific, targeted eradication of human tumor cells.
Similar articles
- Targeted tumor killing via an intracellular antibody against erbB-2.
Deshane J, Siegal GP, Alvarez RD, Wang MH, Feng M, Cabrera G, Liu T, Kay M, Curiel DT. Deshane J, et al. J Clin Invest. 1995 Dec;96(6):2980-9. doi: 10.1172/JCI118370. J Clin Invest. 1995. PMID: 8675670 Free PMC article. - Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.
Deshane J, Cabrera G, Grim JE, Siegal GP, Pike J, Alvarez RD, Curiel DT. Deshane J, et al. Gynecol Oncol. 1995 Oct;59(1):8-14. doi: 10.1006/gyno.1995.1260. Gynecol Oncol. 1995. PMID: 7557620 - An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP, Curiel DT. Wright M, et al. Gene Ther. 1997 Apr;4(4):317-22. doi: 10.1038/sj.gt.3300372. Gene Ther. 1997. PMID: 9176517 - Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity.
Barnes MN, Deshane JS, Siegal GP, Alvarez RD, Curiel DT. Barnes MN, et al. Clin Cancer Res. 1996 Jul;2(7):1089-95. Clin Cancer Res. 1996. PMID: 9816272
Cited by
- pcDNA3.1(-)-mediated ribozyme targeting of HER-2 suppresses breast cancer tumor growth.
He P, Zhu D, Hu JJ, Peng J, Chen LS, Lu GX. He P, et al. Mol Biol Rep. 2010 Mar;37(3):1597-604. doi: 10.1007/s11033-009-9569-4. Epub 2009 May 15. Mol Biol Rep. 2010. PMID: 19444644 - Targeting the function of the HER2 oncogene in human cancer therapeutics.
Moasser MM. Moasser MM. Oncogene. 2007 Oct 11;26(46):6577-92. doi: 10.1038/sj.onc.1210478. Epub 2007 May 7. Oncogene. 2007. PMID: 17486079 Free PMC article. Review. - The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.
Moasser MM. Moasser MM. Oncogene. 2007 Oct 4;26(45):6469-87. doi: 10.1038/sj.onc.1210477. Epub 2007 Apr 30. Oncogene. 2007. PMID: 17471238 Free PMC article. Review. - Genetically engineered intracellular single-chain antibodies in gene therapy.
Bilbao G, Contreras JL, Curiel DT. Bilbao G, et al. Mol Biotechnol. 2002 Oct;22(2):191-211. doi: 10.1385/MB:22:2:191. Mol Biotechnol. 2002. PMID: 12405266 Review. - Gene therapy for carcinoma of the breast: Genetic ablation strategies.
Curiel DT. Curiel DT. Breast Cancer Res. 2000;2(1):45-9. doi: 10.1186/bcr28. Epub 1999 Dec 17. Breast Cancer Res. 2000. PMID: 11250692 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous